Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 6
2003 1
2004 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Relationship between HAART adherence and adipose tissue alterations.
Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, Ridolfo AL, Mazzotta F, Wu AW, d'Arminio Monforte A, Galli M; AdICoNA Study Group. LipoICoNA Study Group. Ammassari A, et al. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S140-4. doi: 10.1097/00126334-200212153-00011. J Acquir Immune Defic Syndr. 2002. PMID: 12562038
Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance.
Murri R, Ammassari A, Trotta MP, De Luca A, Melzi S, Minardi C, Zaccarelli M, Rellecati P, Santopadre P, Soscia F, Scasso A, Tozzi V, Ciardi M, Orofino GC, Noto P, Monforte Ad, Antinori A, Wu AW; AdICoNa Study Group. Murri R, et al. J Gen Intern Med. 2004 Nov;19(11):1104-10. doi: 10.1111/j.1525-1497.2004.30248.x. J Gen Intern Med. 2004. PMID: 15566439 Free PMC article.
Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.
Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, Lo Caputo S, Narciso P, Pauluzzi S, Carosi G, Nappa S, Piano P, Izzo CM, Lichtner M, Rezza G, Monforte A, Ippolito G, d'Arminio Moroni M, Wu AW, Antinori A; AdICONA Study Group. Ammassari A, et al. J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):445-9. doi: 10.1097/00042560-200112150-00006. J Acquir Immune Defic Syndr. 2001. PMID: 11744832
Virologic correlates of adherence to antiretroviral medications and therapeutic failure.
Perno CF, Ceccherini-Silberstein F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, Bellocchi MC, Trotta MP, Piano P, Forbici F, Scasso A, Vullo V, d'Arminio Monforte A, Antinori A; AdICoNA Study Group. Perno CF, et al. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S118-22. doi: 10.1097/00126334-200212153-00006. J Acquir Immune Defic Syndr. 2002. PMID: 12562033 Review.
Treatment-related factors and highly active antiretroviral therapy adherence.
Trotta MP, Ammassari A, Melzi S, Zaccarelli M, Ladisa N, Sighinolfi L, Mura MS, d'Arminio Monforte A, Antinori A; AdICoNA Study Group. Trotta MP, et al. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S128-31. doi: 10.1097/00126334-200212153-00008. J Acquir Immune Defic Syndr. 2002. PMID: 12562035 Review.
Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART.
Antinori A, Cozzi-Lepri A, Ammassari A, Trotta MP, Nauwelaers D, Hoetelmans R, Murri R, Melzi S, Narciso P, Nasta P, Zaccarelli M, Santopadre P, Vecchiet J, Izzo CM, Maonforte Ad; AdICoNA Study Group. Antinori A, et al. Antivir Ther. 2004 Apr;9(2):291-6. Antivir Ther. 2004. PMID: 15134192 Clinical Trial.
Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy.
Starace F, Ammassari A, Trotta MP, Murri R, De Longis P, Izzo C, Scalzini A, d'Arminio Monforte A, Wu AW, Antinori A; AdICoNA Study Group. NeuroICoNA Study Group. Starace F, et al. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S136-9. doi: 10.1097/00126334-200212153-00010. J Acquir Immune Defic Syndr. 2002. PMID: 12562037 Review.
Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens.
Trotta MP, Ammassari A, Cozzi-Lepri A, Zaccarelli M, Castelli F, Narciso P, Melzi S, De Luca A, Monforte AD, Antinori A; Adherence Italian Cohort Naive Antiretrovirals (AdICONA) Study Group; Adherence Spallanzani (AdeSpall) Study Group. Trotta MP, et al. AIDS. 2003 May 2;17(7):1099-102. doi: 10.1097/00002030-200305020-00026. AIDS. 2003. PMID: 12700467